Form 4: Bristol-Myers Squibb Director Phyllis Yale Reports Acquisition of Deferred Share Units
SEC Form 4 Filing
Director Phyllis Yale reports acquisition of deferred share units convertible to common stock in Bristol-Myers Squibb.
Summary
- On September 30, 2024, Phyllis Yale, a director of Bristol-Myers Squibb, acquired 676.459 deferred share units.
- These units are convertible into shares of common stock upon settlement, which occurs when Yale ceases to be a director or at a previously specified future date.
- The price per unit was $51.74.
- Following the transaction, Yale beneficially owns 29,847.867 shares, including deferred compensation and reinvested dividends.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of shares by a director is generally viewed as a positive sign, but it's not a major event.
Positives
- The acquisition of deferred share units by a director signals confidence in the company's future performance.
Future Outlook
The deferred share units will be converted into common stock upon settlement, which occurs when Yale ceases to be a director or at a future date previously specified by the reporting person.
Industry Context
Tracking insider transactions like this is common practice in the financial industry to gauge sentiment and potential future performance of a company. It is typical for directors to receive deferred share units as part of their compensation.
Comparison to Industry Standards
- Director compensation packages often include deferred share units, aligning director interests with long-term shareholder value.
- Comparing the size and vesting schedule of these units to those of directors at comparable pharmaceutical companies like Pfizer (PFE) or Merck (MRK) can provide context on the competitiveness of Bristol-Myers Squibb's compensation practices.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Phyllis Yale acquired deferred share units. |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.